Monopar Therapeutics stock forecast: Selloff remains in focus

Traders Union
All News
Stocks
Monopar Therapeutics drops 3.38% today

Highlights

MNPR/USD stock faces sustained downward pressure in the short and medium term, with a 3.38% decline intraday and continued seller dominance.
Momentum indicators including MACD, ADX, and CCI signal strong bearish bias with deep oversold conditions, showing limited prospect for a rebound.
Expected trading range is $100.60 to $108.35 in the next 2 to 3 sessions, with downside risk rated as very high probability unless price overcomes the $110.81 resistance.

Oversold readings as downward momentum challenges resistance

On the technical front, MNPR is trading below both the MA-20 and MA-50 on the working timeframe, while still holding above the MA-200 on the daily chart. The Ichimoku Kijun marks immediate resistance at $110.81. MACD signals a strong sell, and ADX reflects ongoing downward momentum, with RSI at 37.5 (Sell). CCI and Bull/Bear Power both indicate oversold and seller-dominated conditions, while the Stoch RSI and Awesome Oscillator remain neutral and do not currently confirm the trend. The intraday session shows a gap lower at the open and the stock near its session lows amid moderate volatility, consistent with prevailing negative momentum.

Downside risk dominates as breakout prospects remain limited

Looking ahead, MNPR is expected to trade within a range of $100.60 to $108.35 over the next two to three sessions. The probability of an upward move is rated as very low, with downside risk considered very high. A sustained recovery would require a decisive break above the $110.81 resistance. Should the lower boundary at $100.60 fail, further declines below support may follow. The baseline scenario projects continued sideways-to-lower movement within the flagged range under current volatility conditions.

Anton Kharitonov, expert at Traders Union, notes that Monopar Therapeutics continues to show persistent downside pressure. He sees momentum indicators and moving averages firmly supporting a bearish technical view, with very limited probability of near-term recovery. The outlook is defensive as risk remains high below key resistance. "Until $110.81 is broken with conviction, I see no reason to step in on the long side."

Earlier, analysts noted that Monopar Therapeutics exhibited technical resilience but warned of potential reversal if overbought conditions persisted. The current breakdown below near-term averages, paired with increasing downside risk, signals a material shift in trend direction, making the $100.60 support a critical level to watch for further declines.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.